DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-2.73%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$4.75B
AUM Growth
+$4.75B
(+6.2%)
Cap. Flow
+$377M
Cap. Flow
% of AUM
7.95%
Top 10 Holdings %
Top 10 Hldgs %
38.71%
Holding
141
New
13
Increased
21
Reduced
12
Closed
13
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$52M |
| 2 |
Gilead Sciences
GILD
|
$48.7M |
| 3 |
Cogent Biosciences
COGT
|
$38.6M |
| 4 |
Merus
MRUS
|
$35.1M |
| 5 |
Neurocrine Biosciences
NBIX
|
$34.6M |
Top Sells
| 1 |
Kura Oncology
KURA
|
$32.8M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$22.2M |
| 3 |
Organogenesis Holdings
ORGO
|
$19.6M |
| 4 |
GoodRx Holdings
GDRX
|
$18.9M |
| 5 |
Nuvation Bio
NUVB
|
$18.8M |
Sector Composition
| 1 | Healthcare | 52.41% |
| 2 | Financials | 1.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pharvaris
PHVS
$1.41B
| $26.3M | 0.54% |
1,190,343
-386,735
| -25% | -$8.55M |
|
|
HZNP
27
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $25M | 0.51% |
313,000
-152,000
| -33% | -$12.1M |
|
|
OMIC
28
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $24.2M | 0.5% |
6,336,330
-275,689
| -4% | -$1.05M |
|
29
GeneDx Holdings
WGS
$3.65B
| $23.7M | 0.49% |
18,848,488
+5,000,000
| +36% | +$6.3M |
|
|
BLU
30
DELISTED
BELLUS Health Inc.
BLU
| $22.9M | 0.47% |
2,473,000
-1,199,808
| -33% | -$11.1M |
|
|
31
Organogenesis Holdings
ORGO
$629M
| $21.7M | 0.45% |
4,447,740
-4,009,136
| -47% | -$19.6M |
|
32
Phreesia
PHR
$1.81B
| $21.4M | 0.44% |
+857,115
| New | +$21.4M |
|
33
Syndax Pharmaceuticals
SNDX
$1.39B
| $21.4M | 0.44% |
+1,111,111
| New | +$21.4M |
|
|
AMED
34
DELISTED
Amedisys
AMED
| $20.9M | 0.43% |
+199,000
| New | +$20.9M |
|
35
Tarsus Pharmaceuticals
TARS
$2.44B
| $19.3M | 0.4% |
+1,324,214
| New | +$19.3M |
|
36
Insmed
INSM
$30.3B
| $18.9M | 0.39% |
960,484
+655,912
| +215% | +$12.9M |
|
37
Revolution Medicines
RVMD
$7.43B
| $17.4M | 0.36% |
891,587
| – | – |
|
38
The Oncology Institute
TOI
$302M
| $17.1M | 0.35% |
3,383,099
+86,992
| +3% | +$440K |
|
39
Pacira BioSciences
PCRX
$1.22B
| $17M | 0.35% |
+292,000
| New | +$17M |
|
40
Alphatec Holdings
ATEC
$2.35B
| $15.8M | 0.33% |
2,420,547
-1,174,282
| -33% | -$7.68M |
|
41
AnaptysBio
ANAB
$630M
| $15.7M | 0.32% |
+772,000
| New | +$15.7M |
|
|
DALS
42
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $15.5M | 0.32% |
1,600,000
| – | – |
|
|
INZY
43
DELISTED
Inozyme Pharma
INZY
| $12.9M | 0.27% |
2,696,372
+351,586
| +15% | +$1.68M |
|
|
PROF
44
Profound Medical
PROF
$131M
| $12.5M | 0.26% |
1,713,797
| – | – |
|
45
Kezar Life Sciences
KZR
$28.5M
| $11.7M | 0.24% |
+1,419,000
| New | +$11.7M |
|
46
Larimar Therapeutics
LRMR
$337M
| $11.4M | 0.24% |
5,830,249
| – | – |
|
47
TG Therapeutics
TGTX
$5.03B
| $11.4M | 0.23% |
+2,677,500
| New | +$11.4M |
|
48
Alector
ALEC
$282M
| $10.7M | 0.22% |
1,055,192
| – | – |
|
49
Foghorn Therapeutics
FHTX
$298M
| $10.6M | 0.22% |
777,525
+538,660
| +226% | +$7.33M |
|
|
EUCR
50
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
| $9.9M | 0.2% |
999,999
| – | – |
|